Publication Category: Medications
Changes in Eating Behaviour During Treatment With Obesity Medications
- Chong MC, Ko TYL, le Roux PL, le Roux CW. Changes in Eating Behaviour During Treatment With Obesity Medications Clin Obes
Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m(2), and chronic kidney disease – A randomised, controlled pilot study
- Ozairi EA, Taghadom E, Irshad M, Yousef AA, AlKandari J, Al-Najim W, Alabdulkader S, Miras AD, le Roux CW. Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m(2), and chronic kidney disease – A randomised, controlled pilot study Diabetes Res Clin Pract
Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?
-
Brennan DJ, Lynch L.
Will GLP-1 Agonists Weaken the Links between Obesity and Cancer? Cancer Discov
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
-
le Roux CW, Wharton S, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM.
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) Diabetes Obes Metab
The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice
- Alawami F, Novaes O, Gibney J, Phelan N, Behan LA, Owens L. The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice Ir J Med Sci
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes
-
Wharton S, le Roux CW, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM.
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes Diabetes Obes Metab
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme
-
Pandey A, Moroney M, Verma S, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Petrie MC, Rönnbäck C, Domdey A, Rasmussen S, Chinnakondepalli KM, Patel S, Kosiborod MN.
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme Eur J Heart Fail
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
-
Mondoh A, Crotty M, le Roux CW.
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape Expert Opin Pharmacother
Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial
- Platz E, Kaplan LM, le Roux CW, Wharton S, Burger S, Hussain SA, Brueckmann M, Startseva E, Fey C, Kosiborod MN, Bozkurt B. Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial JACC Heart Fail